FineImmune Biotechnology

Solving technical bottlenecks in tumor microenvironment

Gene and Cell Therapy

About the company

Founded in 2016 by Professor ­­ Penghui Zhou, a leading expert in immuno-oncology in China. The team focuses on solving technical bottlenecks in the microenvironment of solid tumors and has discovered a number of proprietary biomarkers which could be used as targets for anti-cancer cell therapies, including TAL, TCRT and CART.